TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

Highlights TTX-MC138’s Path from Target Discovery to the Clinic

BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that its Chief Scientific Officer, Zdravka Medarova, Ph.D., will present at this year’s RNA Leaders Europe Congress scheduled to take place March 12-14 in Basel, Switzerland. The conference is focused on the development of mRNA, RNAi, ASOs, oligonucleotides, vaccines, microRNAs, genome editing, wider nucleic acids and RNA targets. It is expected that delegates from leading companies in these areas will be in attendance.

Details of the Presentation

• Stream: Short RNA Based Therapeutics
• Title: A First-in-Class Therapy Against Metastatic Cancer: From Pre-Clinical Testing to Early Clinical Trials
• Date and Time: March 14th 2:10 p.m. local time
  

Dr. Medarova’s presentation will describe work completed in support of the TransCode’s ongoing Phase 0 microdose clinical study with its lead therapeutic candidate, TTX-MC138. TTX-MC138 is designed to be delivered to metastatic tumor cells where it is intended to inhibit miR-10b, generally regarded as a master regulator of metastatic disease. In preclinical studies, TTX-MC138 elicited complete responses and life-long disease remission in animal models of adenocarcinoma.

Nonclinical studies to be presented include dosimetry, pharmacokinetics (PK), tissue distribution, and metabolite analysis. In addition, preliminary clinical results including pharmacokinetics and accumulation of the drug candidate in clinical metastases, as well as drug candidate stability, will be discussed. The presentation will also describe key activities completed in support of TransCode’s planned Phase 1/2 trial for which it plans to file an IND in March 2024.

“We are honored to join key stakeholders in the field of RNA to exchange ideas, share compelling data, and ultimately help further this potentially important technology,“ said Medarova. Dr. Medarova continued, “We believe that TTX-MC138 has the potential to help cancer patients as a first-in-class RNA-based treatment for metastatic disease. We are eager to share our progress with the broader scientific community.”

For more information, please visit:

www.transcodetherapeutics.com and https://informaconnect.com/rna-leaders-europe/

About TransCode

TransCode is a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.